Reuters logo
BRIEF-Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700
2017年3月16日 / 中午12点28分 / 6 个月前

BRIEF-Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700

March 16 (Reuters) - Alkermes Plc

* Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700 for treatment of multiple sclerosis

* Alkermes Plc says plans to submit a new drug application (NDA) for ALKS 8700 for treatment of RRMS to U.S. Food and Drug Administration (FDA) in 2018 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below